Treatment of EML4-ALK fusion-positive non-small-cell lung cancer (NSCLC) with the anaplastic lymphoma kinase (ALK)-targeted agent, crizotinib, offers significant improvement of clinical outcomes[1]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.